US FDA approves first epoetin alfa biosimilar for the treatment of anemia
The US Food and Drug Administration (FDA) has approved Retacrit (epoetin alfa-epbx) as a biosimilar to Epogen/Procrit (epoetin alfa) for the treatment of anemia caused by chronic kidney disease, chemotherapy, or use of zidovudine in patients with HIV infection. Retacrit is also approved for use before and after surgery to reduce the chance that red blood cell transfusions will be needed because of blood loss during surgery.
To continue reading this article
Continue reading your article with a Emedinexus account..